Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current topics in melanoma.
Wolchok JD, Saenger YM. Wolchok JD, et al. Among authors: saenger ym. Curr Opin Oncol. 2007 Mar;19(2):116-20. doi: 10.1097/CCO.0b013e32801497c6. Curr Opin Oncol. 2007. PMID: 17272983 Review.
Melanoma immunotherapy.
Sivendran S, Glodny B, Pan M, Merad M, Saenger Y. Sivendran S, et al. Mt Sinai J Med. 2010 Nov-Dec;77(6):620-42. doi: 10.1002/msj.20215. Mt Sinai J Med. 2010. PMID: 21105125 Review.
Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.
Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM. Sivendran S, et al. Among authors: saenger ym. J Invest Dermatol. 2014 Aug;134(8):2202-2211. doi: 10.1038/jid.2014.85. Epub 2014 Feb 12. J Invest Dermatol. 2014. PMID: 24522433 Free PMC article.
Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
Blake Z, Marks DK, Gartrell RD, Hart T, Horton P, Cheng SK, Taback B, Horst BA, Saenger YM. Blake Z, et al. Among authors: saenger ym. J Immunother Cancer. 2018 Apr 6;6(1):25. doi: 10.1186/s40425-018-0338-6. J Immunother Cancer. 2018. PMID: 29622046 Free PMC article.
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS. Morrison C, et al. J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8. J Immunother Cancer. 2018. PMID: 29743104 Free PMC article.
70 results